Bioasis Technologies Inc. (OTCMKTS:BIOAF) Sees Significant Decline in Short Interest
Bioasis Technologies Inc. (OTCMKTS:BIOAF) Sees Significant Decline in Short Interest
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.Bioasis Technologies Inc. (OTCMKTS:BIOAF – Get Rating) saw a significant decrease in short interest during the month of July. As of July 31st, there was short interest totalling 34,600 shares, a decrease of 23.3% from the July 15th total of 45,100 shares. Based on an average daily volume of 29,000 shares, the days-to-cover ratio is currently 1.2 days.
生物綠洲科技公司(BiOasis Technologies Inc.)看到，7月份空頭股數的銷量大幅下降。截至7月31日，空頭股數共有3.46萬股，比7月15日的4.51萬股減少了23.3%。以日均成交量29,000股計算，目前天數與回補比率為1.2天。
Bioasis Technologies Stock Performance
BiOASIS科技股表現
Shares of OTCMKTS BIOAF opened at $0.12 on Friday. The business's 50 day moving average is $0.13 and its 200-day moving average is $0.17. Bioasis Technologies has a 1-year low of $0.10 and a 1-year high of $0.28.
上週五，OTCMKTS BIOAF的股價開盤報0.12美元。該業務的50日移動均線切入位在0.13美元，200日移動均線切入位在0.17美元。BiOasis Technologies的一年低點為0.10美元，一年高位為0.28美元。
Bioasis Technologies (OTCMKTS:BIOAF – Get Rating) last posted its earnings results on Tuesday, June 14th. The company reported ($0.01) earnings per share for the quarter. On average, sell-side analysts forecast that Bioasis Technologies will post -0.05 earnings per share for the current fiscal year.
BiOasis Technologies(OTCMKTS：BIOAF-GET Rating)最近一次公佈財報是在6月14日(星期二)。該公司公佈了本季度每股收益(0.01美元)。賣方分析師平均預測，BiOasis Technologies本財年每股收益將為0.05美元。
About Bioasis Technologies
關於BiOASIS技術公司
Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases.
BiOASIS技術公司是一家處於發展階段的生物製藥公司，致力於神經疾病和障礙的診斷和治療產品的研究和開發。它正在開發xB3，這是一種通過血腦屏障(BBB)運輸治療劑的平臺技術；以及治療中樞神經系統疾病(CNS)，包括腦癌，以及代謝和神經退行性疾病。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Bioasis Technologies (BIOAF)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免費獲取StockNews.com關於BiOASIS技術的研究報告(BIOAF)
- 值得關注的兩場重要的零售股大戰
- MarketBeat：回顧中的一週2012-8-8
- 什麼是WallStreetBets，他們的目標是什麼股票？
- 機構和分析師推動Jack in the Box走高
- 你能猜到哪個電動車股票打敗了特斯拉嗎？
Receive News & Ratings for Bioasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《BiOASIS技術日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對BiOasis Technologies及相關公司的評級的每日摘要。
譯文內容由第三人軟體翻譯。
